Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine in Diabetic Nephropathy
NCT05147194Phase 2Unknown
- Sponsor
- Tongji Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of trimetazidine in diabetic nephropathy (DN) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Ratio of UACR levels to baseline UACR at 6 months. Status: unknown.
02
Drugs
trimetazidine
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT05147194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147194.